Chemistry:Ponazuril
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Marquis |
| AHFS/Drugs.com | FDA Professional Drug Information |
| Routes of administration | Oral |
| ATCvet code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C18H14F3N3O6S |
| Molar mass | 457.38 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Ponazuril (INN), sold by Merial, Inc.,[1] now part of Boehringer Ingelheim,[2] under the trade name Marquis® (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by coccidia Sarcocystis neurona.[3][4] More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia as an intestinal parasite. Coccidia treatment in small animals is far shorter than treatment for EPM.[citation needed]
See also
References
- ↑ "Merial Acquires LEGEND® and MARQUIS®". Boehringer Ingelheim. http://merial.com/en/content-pages/press-releases/merial-acquires-two-major-equine-health-products-from-bayer.
- ↑ "Sanofi and Boehringer Ingelheim confirm Closing of business swap | www.boehringer-ingelheim.com" (in en). https://www.boehringer-ingelheim.com/press-release/sanofi-and-boehringer-ingelheim-confirm-closing-business-swap-january-1st-2017.
- ↑ "Marquis". Drugs.com. https://www.drugs.com/pro/marquis.html.
- ↑ "Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses". American Journal of Veterinary Research 69 (3): 396–402. March 2008. doi:10.2460/ajvr.69.3.396. PMID 18312139.
 |  |
